CytRx Corp. buy melinda
Start price
11.05.17
/
50%
€2.41
Target price
18.05.17
€3.25
Performance (%)
14.13%
End price
18.05.17
€2.75
Summary
This prediction ended on 18.05.17 with a price of €2.75. The prediction had a final performance of 14.13%. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| CytRx Corp. | - | - | - | - |
| iShares Core DAX® | -0.046% | 5.960% | 7.403% | 65.851% |
| iShares Nasdaq 100 | 0.922% | 3.693% | 28.138% | 93.298% |
| iShares Nikkei 225® | 3.014% | 6.638% | 48.886% | 89.079% |
| iShares S&P 500 | -0.359% | 2.747% | 22.530% | 71.942% |
Comments by melinda for this prediction
In the thread CytRx Corp. diskutieren
Gesundheit | Biotechnologie | Vereinigte Staaten
Aldoxorubicine mit Doxorubicin
Krebs Weichteilsarkom feuerfester Krebs